Vimarsana
Biggest News Aggregation in the World

Page 16 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from End Results Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In End Results Program Today - Breaking & Trending Today

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442 - Vimarsana News

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442

/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, today announced...

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series - Vimarsana News

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present detailed results from the Phase 3 GLOW...

Patients undergoing surgery for cancer face higher risk of suicide - Vimarsana News

Patients undergoing surgery for cancer face higher risk of suicide

In a study of U.S. patients who underwent major cancer operations, the incidence of suicide was significantly higher than that observed in the general population.

Cost of Cancer for AYAs Exceeds $250,000 Over a Lifetime - Vimarsana News

Cost of Cancer for AYAs Exceeds $250,000 Over a Lifetime

In the United States, adolescents and young adults (AYAs) with cancer face high economic and human costs throughout their lifetime.

Parents Up in Arms Over California Assembly Bill That Would - Vimarsana News

Parents Up in Arms Over California Assembly Bill That Would

The science is not settled on the Gardasil HPV vaccine. Peer reviewed publications have demonstrated that Merck has oversold the efficacy of its HPV...